Compare TNC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | EYPT |
|---|---|---|
| Founded | 1870 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1994 | 2005 |
| Metric | TNC | EYPT |
|---|---|---|
| Price | $64.84 | $12.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $79.00 | $31.80 |
| AVG Volume (30 Days) | 305.5K | ★ 1.2M |
| Earning Date | 04-29-2026 | 03-04-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,137,600,000.00 | $7,539,000.00 |
| Revenue This Year | $5.44 | N/A |
| Revenue Next Year | $5.28 | $1,031.72 |
| P/E Ratio | $28.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $60.18 | $3.91 |
| 52 Week High | $85.91 | $19.11 |
| Indicator | TNC | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 33.83 |
| Support Level | $60.18 | $11.21 |
| Resistance Level | $84.24 | $12.24 |
| Average True Range (ATR) | 1.88 | 0.76 |
| MACD | 0.80 | -0.21 |
| Stochastic Oscillator | 42.06 | 0.83 |
Tennant Co is engaged in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, and asset management solutions. Its products are used in many types of environments, including retail establishments, distribution centers, factories and warehouses, public venues such as arenas and stadiums, office buildings, schools, and more.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.